biei resources

Product Information Sheet for NR-59591

SUPPORTING INFECTIOUS DISEASE RESEARCH

Pretomanid (PA-824)

Catalog No. NR-59591

For research use only. Not for use in humans.

Contributor and Manufacturer:

Mylan Laboratories Limited, Hyderabad, Telangana, India

Product Description:

Pretomanid [PA-824; (S)-PA-824; Dovprela[®]] is a novel antimycobacterial used in treating multidrug-resistant tuberculosis (MDR-TB) and is a member of the nitroimidazooxazine class (whereas delamanid is a member of the nitroimidazooxazole class). Its mechanism of action is complex and has not been fully elucidated. Under aerobic conditions, pretomanid appears to inhibit *Mycobacterium tuberculosis* (*M. tuberculosis*) cell wall biosynthesis by inhibiting the synthesis of mycolic acid; under anaerobic conditions, it generates reactive nitrogen species. Pretomanid is effective in both actively replicating *M. tuberculosis* and in dormant bacilli (both bactericidal and sterilizing activity). It is generally used together with bedaquiline and linezolid.^{1,2,3}

Material Provided:

Each vial contains approximately 40 mg of pretomanid.

Packaging/Storage:

NR-59591 was packaged in plastic cryovials and is provided on refrigerated bricks. NR-59591 should be stored at room temperature protected from light and moisture immediately upon arrival. The vial should be centrifuged prior to opening.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Pretomanid (PA-824), NR-59591."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in Microbiological and Biomedical Laboratories (BMBL)</u>. 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government makes any

warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC^{\otimes} nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Conradie, F., et al. "Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis." <u>N. Engl. J.</u> <u>Med.</u> 387 (2022): 810-823. PubMed: 36053506.
- Gils, T., et al. "Pretomanid for Tuberculosis: A Systematic Review." <u>Clin. Microbiol. Infect.</u> 28 (2022): 31-42. PubMed: 34400340.
- Committee for Medicinal Products for Human Use (CHMP). (2020). "Pretomanid FGK: EPAR - Public Assessment Report." <u>European Medicines Agency</u>.

 $\mathsf{ATCC}^{\circledast}$ is a trademark of the American Type Culture Collection.

